Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26071-26080 Newer>

The Motley Fool September 13, 2007 Emil Lee	The Holy Grail of Investing Buybacks plus free cash flow growth equals fireworks. Investors, here are five stocks to consider that fit this description: Sears Holdings... US Bancorp... Moody's... Torchmark... American Express...
The Motley Fool September 13, 2007 Lawrence A. Rothman	The Money Stacks Up at Dollar Financial The bank turns in strong quarterly results, attributed in part to diversity that some competitors don't have.
The Motley Fool September 13, 2007 Emil Lee	Quick Take: optionsXpress's X-Factor The latest monthly results from the online broker prove inconclusive. Investors take note.
The Motley Fool September 13, 2007 Brian Lawler	Don't Bet on the Dendreon Lawsuit A patient advocacy group files a lawsuit attempting to usher Dendreon's prostate cancer drug Provenge onto the market after the FDA has withheld approval. Investors should take note.
The Motley Fool September 13, 2007 Dave Mock	Qualcomm Wins on a Split Decision Between Qualcomm and Broadcom, victory is in the eye of the beholder. Qualcomm did earn a significant, but only partial, victory in the latest ruling, as the ban on its chips remained in effect for some carriers.
The Motley Fool September 13, 2007 Brian Lawler	ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux.
The Motley Fool September 13, 2007 Brian Orelli	Progenics Progresses Progenics and partner Wyeth announce plans to start three new clinical trials on their constipation-relieving drug. The patient treatment time for the trials is relatively short, so investors won't have to wait too long to see how the drug performs.
The Motley Fool September 13, 2007 Brian Lawler	Cardiome at a Glance Cardiome Pharma gives investors an overview of where its lead Cardiac drug stands; a New Drug Application has been submitted to the FDA.
The Motley Fool September 13, 2007 Brian Orelli	Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note.
The Motley Fool September 13, 2007 Rich Smith	CarMax Guns Its Growth The used-car specialist plans to grow by opening more small stand alone locations, and driving comps by reducing the average retail price. Investors take note.
<Older 26071-26080 Newer> Return to current articles.